tirzepatide nhs vs Semaglutide UK: Mounjaro vs Wegovy Guide How the weight loss drug

The biggest safety concern is heart health

The unpredictability adds psychological stress on top of the physical frustration

Whilst cardiometabolic risk factors were included as secondary endpoints, providing information on the potential impact of cardiovascular factors, these studies are not designed to assess this impact

Phase 2 trial results (48 weeks, adults with obesity): 1 mg dose: 7.2% body weight loss 4 mg dose: 12.9% body weight loss 8 mg dose: 17.3% body weight loss 12 mg dose: 24.2% body weight loss Placebo: 1.6% body weight loss Phase 3 TRIUMPH-4 results: 9 mg dose: 20.0% body weight loss (22.9 kg / 50.5 lbs) 12 mg dose: 23.7% body weight loss (27.2 kg / 60.0 lbs) Placebo: 4.6% body weight loss In a separate phase 3 analysis, retatrutide at the highest dose achieved up to 28.7% weight loss